IGF2 preserves osteosarcoma cell survival by creating an autophagic state of dormancy that protects cells against chemotherapeutic stress

Osteosarcoma (OS) is a malignant bone tumor in children and adolescents characterized by intrinsic therapeutic resistance. The insulin-like growth factor IGF2 is expressed at elevated levels in OS after treatment with chemotherapy, prompting an examination of its functional contributions to resistance. We found that continuous exposure to IGF2 or insulin in the absence of serum created a dormant growth state in OS cells that conferred resistance to various chemotherapeutic drugs in vitro. Mechanistic investigations revealed that this dormant state correlated with downregulation of downstream signaling by the IGF1 receptor, heightened cell survival, enhanced autophagy and the presence of extracellular glutamine. Notably, inhibiting autophagy or depleting glutamine was sufficient to increase chemotherapeutic sensitivity in OS xenografts in mice. Clinically, we confirmed that IGF expression levels were elevated in human OS specimens from patients who received chemotherapy. Together, our results suggest that activation of IGF or insulin signaling preserves the survival of OS cells under chemotherapeutic stress, providing a drug resistant population that may engender minimal residual disease. Attenuating this survival mechanism may help overcome therapeutic resistance in OS.